Roflumilast is a clinically available selective PDE-4 inhibitor with anti-inflammatory effects that is commonly administered to chronic obstructive pulmonary disease (COPD) patients suffering from chronic bronchitis46–49. The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.